Table 3.
Predictive factors for the onset of endocrine toxicity during treatment with nivolumab or pembrolizumab
| Predictor | Toxicity | Chi2 | p | |||
|---|---|---|---|---|---|---|
| No | Yes | |||||
| Gender | ||||||
| Male | 119 | 76.8% | 36 | 23.2% | 4.381 | 0.036 |
| Female | 62 | 64.6% | 34 | 35.4% | ||
| Type of tumor | ||||||
| Head-Neck | 2 | 100.0% | 0 | 0.0% | 5.647 | 0.342 |
| Breast | 3 | 75.0% | 1 | 25.0% | ||
| Melanoma | 48 | 78.7% | 13 | 21.3% | ||
| NSCLC | 120 | 69.4% | 53 | 30.6% | ||
| Kidney | 8 | 80.0% | 2 | 20.0% | ||
| Bladder | 0 | 0.0% | 1 | 100.0% | ||
| Age | ||||||
| Average age | 70.52 | n/a | 70.8 | n/a | 0.176 | 0.860 |
| Nivolumab vs Pembrolizumab | ||||||
| Nivolum ab | 112 | 72.7% | 42 | 27.3% | 0.075 | 0.784 |
| Pembrolizumab | 69 | 71.1% | 28 | 28.9% | ||
| Previous endocrine disease | ||||||
| No | 156 | 78.4% | 43 | 21.6% | 18.840 | 0.00001 |
| Yes | 25 | 48.1% | 27 | 51.9% | ||